learn Fluridil
a topical anti-androgen with less systemic involvement
Search
forLearn
5 / 14 resultslearn Epidermal Growth Factor
learn sh-Polypeptide-7
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Alfatradiol
a synthetic estrogen used topically as an anti-androgen
Research
5 / 1000+ results
research Steroid Sulfatase Inhibitors: Therapeutic Applications and Development
Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.
research Exploring the Versatility of Microemulsions in Cutaneous Drug Delivery: Opportunities and Challenges
Microemulsions could improve skin drug delivery but face challenges like complex creation and potential toxicity.
research Inhalation Therapy for Repairing Damaged Elastin Fibers and Decelerating Elastinolysis in Chronic Obstructive Pulmonary Disease
Inhalation therapy may repair and protect elastin in the lungs of COPD patients.
research Potential of Nano-Phytochemicals in Cervical Cancer Therapy
Nano-sized plant-based chemicals could improve cervical cancer treatment by being more effective and causing fewer side effects than current methods.
research Skin Metabolism in Obesity: A Narrative Review
Obesity harms skin health by causing inflammation and delayed wound healing.
Community Join
5 / 1000+ resultscommunity Does pyrilutamide degrade to an inactive form if it goes systemic like fluridil
Pyrilutamide's systemic degradation is unclear, unlike fluridil, which becomes inactive in the body. The discussion focuses on whether pyrilutamide shares this property.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community A concern regarding the upcoming androgen degrader drug GT20029
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community how does my progress look 18M 3 months on fin 1mg daily
An 18-year-old male's successful hair regrowth after three months of using finasteride 1mg daily. He reported no side effects and other users expressed admiration and curiosity about his results.